NCT00356681 - A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer | Biotech Hunter

Enrollment

282

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

August 31, 2012

Conditions

Breast NeoplasmsBreast TumorsBreast CancerLocally Recurrent and Metastatic Breast Cancer

Interventions

DRUG

AMG 706 placebo

Blinded placebo

DRUG

Bevacizumab

Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.

DRUG

AMG 706

AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.

DRUG

Paclitaxel

Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.